The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Phase II study of naratuximab emtansine plus rituximab in DLBCL and other B-NHLs
Moshe Y. Levy, MD, Baylor Charles A. Sammons Cancer Center, Dallas, TX, discusses the results of a Phase I trial of naratuximab emtansine, an antibody-drug conjugate targeting CD37, in combination with rituximab for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and other types of B-cell non-Hodgkin lymphoma (B-NHL). Out of 100 patients enrolled in the study, 80 had DLBCL and 20 had other B-NHLs. Dr Levy discusses the poor prognosis for patients with R/R DLBCL who are not eligible for transplantation, and gives an overview of the rationale for the trial. Dr Levy reports that the drug combination demonstrated promising efficacy and was well-tolerated. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
